Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MicroRNAs01:22

MicroRNAs

21.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.0K
Abnormal Proliferation02:23

Abnormal Proliferation

4.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
The Ras Gene02:38

The Ras Gene

6.1K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.1K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

3.8K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High mobility group box 1 (HMGB1) levels in the placenta and in serum in preeclampsia.

American journal of reproductive immunology (New York, N.Y. : 1989)·2011
Same author

Destabilization of coxsackievirus b3 genome integrated with enhanced green fluorescent protein gene.

Intervirology·2011
Same author

[Clinicopathological features of primary splenic histiocytic sarcoma: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi·2011
Same author

[Comparison of treatment with micro endoscopic discectomy and posterior lumbar interbody fusion using single and double B-Twin expandable spinal spacer].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2011
Same author

Virtual transplantation in designing a facial prosthesis for extensive maxillofacial defects that cross the facial midline using computer-assisted technology.

The International journal of prosthodontics·2011
Same author

Total synthesis of phorboxazole A via de novo oxazole formation: convergent total synthesis.

Journal of the American Chemical Society·2010

Related Experiment Video

Updated: May 10, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

Modulation of RASD2 by miRNA-485-5p Drives Thyroid Cancer Progression and Metastasis.

Xiao-Yu Li1, Jian-Ping Sun2, Hao Guo1

  • 1Department of Thyroid and Breast Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

The Kaohsiung Journal of Medical Sciences
|April 28, 2025
PubMed
Summary

Ras Homolog Enriched In Striatum (RASD2) is upregulated in thyroid cancer, promoting tumor progression and metastasis. Inhibiting RASD2, regulated by microRNA-485-5p, shows therapeutic potential for thyroid carcinoma.

Keywords:
RASD2miRNA‐485‐5ppapillary thyroid cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.5K

Related Experiment Videos

Last Updated: May 10, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.5K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

17.5K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Thyroid carcinoma is a significant health concern with complex progression mechanisms.
  • Identifying key molecular drivers and regulatory pathways is crucial for effective therapeutic strategies.

Purpose of the Study:

  • To investigate the role of Ras Homolog Enriched In Striatum (RASD2) in thyroid cancer progression.
  • To elucidate the regulatory relationship between RASD2 and microRNA-485-5p.
  • To evaluate the therapeutic potential of targeting the RASD2 pathway in thyroid carcinoma.

Main Methods:

  • Bioinformatic analysis of public databases and clinical specimens.
  • Immunohistochemistry and qRT-PCR for gene expression validation.
  • In vitro functional assays (proliferation, invasion, glycolysis) and in vivo xenograft/metastasis models.
  • Molecular studies to confirm miRNA-target interactions.

Main Results:

  • RASD2 is significantly upregulated in thyroid cancer, correlating with advanced stage, metastasis, and invasion.
  • RASD2 knockdown suppresses proliferation, invasion, and glycolysis in thyroid cancer cells.
  • MicroRNA-485-5p acts as a negative regulator of RASD2, exhibiting tumor-suppressive effects.
  • Inhibition of RASD2 reduces tumor growth and metastasis in vivo.

Conclusions:

  • The microRNA-485-5p/RASD2 axis is a critical regulatory pathway in thyroid cancer.
  • RASD2 is a potential therapeutic target for thyroid carcinoma.
  • This study provides novel insights into thyroid cancer pathogenesis and treatment.